Thermo Fisher Scientific acquires PPD

The company will offer a comprehensive suite of best services

Thermo Fisher Scientific acquires PPD
Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific, welcomed PPD colleagues to the company

Thermo Fisher Scientific, the world leader in serving science, announced that it has completed its acquisition of PPD, a leading global provider of clinical research services to the biopharma and biotech industry, for US$17.4 billion.

“We are very excited to welcome our PPD colleagues to Thermo Fisher Scientific officially,” said Marc N. Casper, chairman, president, and chief executive officer at the company. “Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD’s leading clinical research services advances our work in bringing life-changing therapies to market, benefiting patients around the world.”

Thermo Fisher’s acquisition will benefit patients globally

As previously announced, the transaction is expected to contribute US$1.50 to Thermo Fisher’s adjusted earnings per share in 2022.1Details of the 2021 impact will be provided during Thermo Fisher’s fourth-quarter earnings call in early 2022.

Thermo Fisher continues to expect to realize total synergies of approximately US$125 million by year three following close, consisting of approximately US$75 million of cost synergies and approximately US$50 million of adjusted operating income benefit from revenue-related synergies. In connection with the acquisition, the company will also assume approximately US$3.0 billion in net debt of PPD. All assumed debt will be retired in connection with the closing of the transaction.2

With the addition of PPD, the company will offer a comprehensive suite of world-class services across the clinical development spectrum − from scientific discovery to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.

In connection with the completion of the transaction, PPD’s common stock ceased trading on Nasdaq prior to the opening of trading. PPD will become part of Thermo Fisher’s laboratory products and services segment.

1 Adjusted earnings per share is a non-Gaap measure that excludes certain items detailed later in this press release under the heading ‘Use of Non-GAAP Financial Measures.’

2 This includes PPD’s outstanding 4.625% Senior Notes due 2025 and 5.000% Senior Notes due 2028 issued by Jaguar Holding Company II and PPD Development, L.P. and guaranteed by PPD, the holders of which have been notified that PPD will redeem all of such notes at the redemption prices specified in the governing indenture, plus interest through the redemption date 18 December, 2021.



Please enter your comment!
Please enter your name here